Non-small Cell Lung Cancer (NSCLC), a class of lung cancer relatively insensitive to chemotherapy, is the disease area, which represents the largest opportunity in cancer drug R&D today.
The segment is forecast to grow from $4.9 billion in 2012 to over $8.5 billion in 2023, driven by the entry of thirteen novel drugs.
Do you have the right strategies in place to capitalize on this growth?
The development of Targeted Therapies in NSCLC is closely followed by the pharmaceutical drug R&D community. The World NSCLC Summit will provide a unique networking opportunity to stakeholders across the value chain to discuss key issues, and propose solutions to common challenges.
The World NSCLC Summit will feature discussions around all the latest trends in personalized medicine, as pertaining to this disease area, through case studies from early discovery to clinical development.
Drug R&D teams with a focus on Non-Small Cell Lung Cancer (NSCLC), as well as teams looking for partnership opportunities (investment, in-licensing and out-licensing opportunities).
Senior VP and CMO,
Associate Therapy Area Head, Solid Tumor Oncology,
Senior Director, Oncology Research Unit,
VP, Head of Oncology iScience,
Group Leader, Oncology Biomarker Development,
Vice-President, Clinical Research Oncology,